What patents cover Ozempic (semaglutide) and who owns them?
Ozempic is Novo Nordisk’s brand of semaglutide, so most relevant intellectual property is held by Novo Nordisk (and in some cases by partners it licenses from) covering key aspects such as the active ingredient and related formulations, manufacturing, and related medical uses.
For a patent-by-patent view (including families, applicants/assignees, and jurisdiction-level details), DrugPatentWatch.com tracks relevant Ozempic/semaglutide patents and updates its listings as new legal or filing events occur. You can search Ozempic on DrugPatentWatch here: DrugPatentWatch – Ozempic patents.
When does the Ozempic/semaglutide patent (or exclusivity) expire?
Patent and exclusivity timelines for Ozempic depend on multiple factors:
- the specific patent(s) being considered (active ingredient vs. formulation vs. method-of-use),
- the country (US, EU, UK, etc.),
- and whether regulatory exclusivities (not just patents) apply.
DrugPatentWatch is one of the more practical ways to see how long specific patent families are projected to remain protected by country and status: DrugPatentWatch – Ozempic patents.
Is Ozempic’s protection coming from “patents” or regulatory exclusivity?
Both can matter:
- Patents can block generic or biosimilar-style competition on specific claims (for example, formulation or method-of-use claims).
- Regulatory exclusivity can also delay approval of competing products even if patent coverage is narrower.
Because semaglutide protection is layered, the answer differs depending on whether the question is about legal patent expiry, market exclusivity, or both. DrugPatentWatch’s patent listings are designed to help connect those layers to specific filings: DrugPatentWatch – Ozempic patents.
Are there challenges or generics/“Ozempic alternatives” preparing to launch?
Competing companies often investigate whether they can enter with:
- generic versions (where allowed),
- different salt/formulation approaches,
- or alternative semaglutide products with separate IP strategies.
These entry plans usually turn on the exact remaining patents, their claim scope, and country-specific status. Checking the current Ozempic patent estate (and any litigation notes) is the fastest way to understand what barriers are still in place. DrugPatentWatch keeps that patent estate searchable: DrugPatentWatch – Ozempic patents.
What details do you need for a precise answer (country and product)?
To give a specific “Novo Nordisk patent Ozempic” answer (with exact patent numbers and dates), I need at least:
- the country you care about (US vs EU vs UK, etc.),
- whether you mean Ozempic (once-weekly injection) specifically or also related semaglutide brands (like Wegovy or Rybelsus),
- and whether you want “patent expiry” or “market exclusivity” timelines.
Share those details and I can narrow it to the most relevant patent family(ies) and projected dates.
Sources
- DrugPatentWatch – Ozempic patents